Structure Therapeutics (GPCR) Earnings Date, Estimates & Call Transcripts $27.47 -1.57 (-5.41%) (As of 12:34 PM ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Structure Therapeutics Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Structure Therapeutics and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataGPCR Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.GPCR Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Structure Therapeutics Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.20-$0.19-$0.20Q2 20242-$0.20-$0.20-$0.20Q3 20242-$0.21-$0.19-$0.20Q4 20243-$0.21-$0.19-$0.20FY 20249-$0.82-$0.77-$0.80Q1 20252-$0.24-$0.18-$0.21Q2 20252-$0.26-$0.18-$0.22Q3 20252-$0.28-$0.24-$0.26Q4 20252-$0.31-$0.22-$0.27FY 20258($1.09)($0.82)($0.96) Structure Therapeutics Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails8/8/2024--$0.23-$0.18+$0.05-$0.18--5/9/2024Q1 2024-$0.21-$0.19+$0.02-$0.19--3/8/2024Q4 2023-$0.21-$0.17+$0.04-$0.17--11/14/2023Q3 2023-$0.22-$0.21+$0.01-$0.21--8/10/2023Q2 2023-$0.19-$0.20 -$0.01-$0.20--5/11/2023Q1 2023-$0.34-$0.25+$0.09-$0.25-- Get the Latest News and Ratings for GPCR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Structure Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Structure Therapeutics Earnings - Frequently Asked Questions How much profit does Structure Therapeutics generate each year? Structure Therapeutics (NASDAQ:GPCR) has a recorded net income of -$89.62 million. GPCR has generated -$0.74 earnings per share over the last four quarters. What is Structure Therapeutics's EPS forecast for next year? Structure Therapeutics's earnings are expected to grow from ($0.82) per share to ($0.58) per share in the next year. More Earnings Resources from MarketBeat Related Companies Legend Biotech Earnings Date Nuvalent Earnings Date Cytokinetics Earnings Date Elanco Animal Health Earnings Date Blueprint Medicines Earnings Date Ionis Pharmaceuticals Earnings Date Corcept Therapeutics Earnings Date Grifols Earnings Date BridgeBio Pharma Earnings Date TG Therapeutics Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles S&P 500 Earnings Set to Shine: January's Critical Market TestCiena Rebounds: AI and Strong Guidance Drive Post-Earnings SurgeHistory Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Has Trump Finally Gone Too Far? (Ad)Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover This page (NASDAQ:GPCR) was last updated on 12/30/2024 by MarketBeat.com Staff From Our PartnersViral Trump video releasedPorter Stansberry’s latest video is going viral… In this bombshell exposé, famed economist Porter Stansberr...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Structure Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Structure Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
